Effect observation of fibrinolytic enzyme combined with lipoic acid on type 2 diabetes peripheral neuropathy
Objective To explore the effect of fibrinolytic enzyme combined with lipoic acid on type 2 diabetes peripheral neuropathy.Methods 65 patients with type 2 diabetes peripheral neuropathy were randomly divided into a control group(32 cases)and an experimental group(33 cases).The control group was treated with metformin tablets orally,while the experimental group was treated with a combination of lipoic acid and fibrinolytic enzyme.Comparison was made on therapeutic effect,blood glucose(fasting blood glucose,2 h postprandial blood glucose)level,nerve(median nerve,superficial peroneal nerve,common peroneal nerve)conduction velocity,adverse reactions(chest tightness,diarrhea,nausea and vomiting)between the two groups.Results The total effective rate of the experimental group was 93.94%,which was higher than the control group's 68.75%(P＜0.05).After treatment,the fasting blood glucose and 2 h postprandial blood glucose levels decreased in both groups;the fasting blood glucose and 2 h postprandial blood glucose in the experimental group were(5.01±0.21)and(8.21±0.51)mmol/L,which were lower than(6.12±0.33)and(10.63±0.55)mmol/L in the control group(P＜0.05).After treatment,the nerve conduction velocity of median nerve,superficial peroneal nerve and common peroneal nerve in both groups increased compared with those before treatment;the nerve conduction velocity of median nerve in the experimental group was(55.71±2.84)m/s,the nerve conduction velocity of superficial peroneal nerve was(45.87±4.11)m/s,and the nerve conduction velocity of common peroneal nerve was(42.84±3.21)m/s,which were higher than(51.69±2.77),(40.81±3.06)and(40.06±2.79)m/s in the control group(P＜0.05).The experimental group had lower incidence of adverse reactions of 9.09%than 34.38%in the control group(P＜0.05).Conclusion Combined treatment of lipoic acid and fibrinolytic enzyme can improve blood glucose level and accelerate nerve conduction velocity in patients with type 2 diabetes peripheral neuropathy;At the same time,it can also reduce adverse reactions and enhance clinical efficacy,which is worth promoting.
Type 2 diabetesPeripheral neuropathyLipoic acidFibrinolytic enzymeClinical efficacy
万方数据
维普
